Implementación de la estrategia basal plus en la práctica clínica

The Diabetes Control and Complications Trial Research Group, 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 Ohkubo, 1995, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res Clin Pract, 28, 103, 10.1016/0168-8227(95)01064-K American Diabetes Association, 2010, Standards of Medical Care in Diabetes-2010, Diabetes Care, 33, S11, 10.2337/dc10-S011 Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 541, 10.4158/EP.15.6.540 UKPDS Study Group, 1998, UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes, Diabetes Care, 21, 87, 10.2337/diacare.21.1.87 IDF Clinical Guidelines Task Force, 2006, Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care, Diabet Med, 23, 579, 10.1111/j.1464-5491.2006.01918.x Cryer, 1999, Hypoglycemia is the limiting factor in the management of diabetes, Diabetes Metab Res Rev, 15, 42, 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO;2-B NICE clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes. March 2010. Available on: www.nice.org.uk. Riddle, 2003, The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 26, 3080, 10.2337/diacare.26.11.3080 Yki-Jarvinen, 2006, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, Diabetologia, 49, 442, 10.1007/s00125-005-0132-0 Yki-Jarvinen, 2008, Initiate Insulin by Aggressive Titration and Education (INITIATE). A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups, Diabetes Care, 31, 1305 Schreiber, 2008, The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of every day clinical practice, Diabetes Technol Ther, 10, 121, 10.1089/dia.2007.0265 Owens, 2009, Adding a single dose of insulin glulisine to basal insulin glargine plus oral antihyperglycemic drug therapy improves glycemic control in type 2 diabetes: a 6-month proof of concept study, Diabetes, 58, A122 Lankisch, 2008, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Orals Plus Apidra and Lantus (OPAL) study group, Diabetes Obes Metab, 10, 1178 Davidson, 2009, Effects of 1, 2 or 3 prandial injections of insulin glulisine on glycemic control in type 2 diabetes patients on insulin glargine and oral drugs, Diabetes, 58, A132 Mullins, 2007, Negative binomial meta-regression analysis of combined glycosilated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus, Clin Ther, 29, 1607, 10.1016/j.clinthera.2007.08.020 Monami, 2008, Long-acting insulin analogues versus NPH human insulin in type 2 diabetes, A meta-analysis. Diab Res Clin Pract, 81, 184, 10.1016/j.diabres.2008.04.007 Hermansen, 2006, A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-náïve people with type 2 diabetes, Diabetes Care, 29, 1269, 10.2337/dc05-1365 Rosenstock, 2008, A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes, Diabetologia, 51, 408, 10.1007/s00125-007-0911-x Janka, 2005, Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes, Diabetes Care, 28, 254, 10.2337/diacare.28.2.254 Raskin, 2005, Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs, Diabetes Care, 28, 260, 10.2337/diacare.28.2.260 Malone, 2005, Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes, Diabet Med, 22, 374, 10.1111/j.1464-5491.2005.01511.x Bretzel, 2008, Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial, Lancet, 29, 1073, 10.1016/S0140-6736(08)60485-7 Hirsch, 2005, A real-word approach to insulin therapy in primary care practice, Clin Diabetes, 23, 78, 10.2337/diaclin.23.2.78 Monnier, 2006, Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities, Diabetes Metab, 32, 7, 10.1016/S1262-3636(07)70241-0 Boehm, 2002, Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients, Diabet Med, 19, 393, 10.1046/j.1464-5491.2002.00733.x Ampudia-Blasco, 2008, Estrategias de insulinización en la diabetes mellitus tipo 2, Av Diabetol, 24, 7 Bergenstal, 2006, Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on pre-prandial glucose patterns is a safe and effective alternative to carbohydrate counting (Carb Count), Diabetes, 55, 444-p Raccah, 2007, When basal insulin therapy in type 2 diabetes is not enough -what next?, Diabetes Metab Res Rev, 23, 257, 10.1002/dmrr.733 Owens, 2009, Algorithm for the introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy, Practical Diabetes Int, 26, 70, 10.1002/pdi.1339 Mooradian, 2006, Narrative review: a rational approach to starting insulin therapy, Ann Intern Med, 145, 125, 10.7326/0003-4819-145-2-200607180-00010 Home, 1998, Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group, Diabetes Care, 21, 1904, 10.2337/diacare.21.11.1904 Rave, 2006, Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes, Diabetes Care, 29, 1812, 10.2337/dc06-0383